Ruzasvir/Uprifosbuvir

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameRuzasvir/Uprifosbuvir
Drug Alias NameUprifosbuvir and RuzasvirRuzasvir and UprifosbuvirUprifosbuvir/RuzasvirMK-3682C
ClassificationSmall molecules > Nucleosides and nucleotide derivtives
Mechanisms of ActionNonstructural protein 5A inhibitorsHepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors
TargetsHepatitis C virus NS5B RNA-dependent RNA polymeraseNonstructural protein 5A
Therapy Area/IndicationsHepatitis C, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes UprifosbuvirRuzasvir
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerck Sharp & Dohme LLC
Active IndicationsN/A
Inactive IndicationsHepatitis C, Chronic

Other Information

ATC CodeN/A
Related LinksN/A